Evidence map›Paper›PMID 41931132›Full record

ArticleCancer causes & control : CCC2026

Statins and postmenopausal breast cancer risk; results from the KARMA cohort.

Marie Klintman, Ann H Rosendahl, Benjamin R Johannesen, Deirdre Cronin-Fenton, Mikael Eriksson, Kamila Czene, Per Hall, Signe Borgquist

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marie KlintmanDepartment of Clinical Sciences Lund, Oncology, Lund University, Skåne University Hospital, 221 85, Lund, SE, Sweden. marie.klintman@med.lu.se.
Ann H RosendahlDepartment of Clinical Sciences Lund, Oncology, Lund University, Skåne University Hospital, 221 85, Lund, SE, Sweden.
Benjamin R JohannesenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Deirdre Cronin-FentonDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Mikael ErikssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Kamila CzeneDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Per HallDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Signe BorgquistDepartment of Clinical Sciences Lund, Oncology, Lund University, Skåne University Hospital, 221 85, Lund, SE, Sweden.

Funding

Fru Berta Kamprads Stiftelse FBKS-2018-R22 (167)Governmental Funding of Clinical Research within the National Health Service Sweden ALF; 2018-Project 0211 ARMärit and Hans Rausing Initiative Against Breast Cancer Personal donation
6 · The paper itself

Abstract

purposeTo study the incidence and subtype of breast cancer in relation to incident and prevalent statin use in a contemporary Swedish prospective cohort, The Karolinska Mammography Project for Risk Prediction of Breast Cancer, KARMA.

methodsA total of 35,315 postmenopausal women attending mammography and included in the KARMA cohort (Jan 2011-March 2013) with data on statin use and potential confounders were studied. During eight years of follow-up, 785 incident invasive breast cancer cases were identified.

resultsA total of 16% of women were prevalent statin users (prior to study inclusion) and 9% were incident statin users (following study inclusion). In multivariable Cox regression analyses, there was no significant association between incident or prevalent statin use and risk of incident breast cancer (HR

conclusionThis prospective population-based study performed in a modern screening population with a substantial number of statin users, concurs with previous publications showing no evidence of an association between statin use and risk of postmenopausal breast cancer.

Indexed as

Breast NeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsPostmenopauseAgedCohort StudiesFemaleHumansIncidenceMammographyMiddle AgedProspective StudiesRisk FactorsSwedenHydroxymethylglutaryl-CoA Reductase InhibitorsBMIBreast cancer riskBreast cancer subtypesObesityOverweightStatins

Identifiers

PMID41931132
PMCPMC13048920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.